Although a novel oral antiviral agent can improve short‐term COVID‐19 outcomes, its effects
on the long‐term outcomes, namely the risk of major adverse cardiovascular events …

Background This study assessed the clinical efficacy of nirmatrelvir plus ritonavir (NMV-r) in
treating patients with COVID-19 who have preexisting cardiovascular diseases (CVDs) …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …

Objectives This study aimed to determine the association of early use of oral antiviral drugs
(including nirmatrelvir-ritonavir and molnupiravir) with the risk of PCC and compare the …

Several randomized controlled trials and real‐world cohort studies have demonstrated the
efficacies of nirmatrelvir plus ritonavir (NMV‐r) and molnupiravir (MOV) in at‐risk patients …

Background Real-world data is currently limited on the association between oral antiviral
therapy and healthcare system burden in patients with mild-to-moderate COVID-19. This …

Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …

Antiviral treatment reduces the severity and mortality of SARS-CoV-2 infection; however, its
effectiveness against long COVID-19 is unclear. This study aimed to evaluate the …

Background Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for
COVID-19 treatment, but direct comparisons of their effectiveness have been limited. This …